Systematic Review
Published on 14 Feb 2025
Global research prospects and trends in TFH cells and tumors: a bibliometric analysis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1443890
- 197 views
Type at least 3 characters
1,374 articles
Articles
Review
Published on 14 Feb 2025
Are all programmed cell death protein 1 inhibitors the same?
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1535030
- 175 views
Original Research
Accepted on 13 Feb 2025
Circulating cell-free DNA methylation analysis of pancreatic cancer patients for early noninvasive diagnosis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1552426
Original Research
Accepted on 12 Feb 2025
Integrated single-cell analysis reveals the regulatory network of Disulfidptosis-related lncRNAs in bladder cancer: Constructing a prognostic model and predicting treatment response
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1527036
Case Report
Published on 12 Feb 2025
Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1483117
- 298 views
Case Report
Accepted on 11 Feb 2025
Case report: metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1549232
Original Research
Accepted on 11 Feb 2025
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1385304
Review
Accepted on 11 Feb 2025
Research and progress of microRNA-136 in metastatic tumors Author Names
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1555270
Review
Accepted on 10 Feb 2025
Advances in targeting protein S-palmitoylation in tumor immunity and therapy
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1547636
Original Research
Accepted on 07 Feb 2025
Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1524861
Case Report
Published on 07 Feb 2025
Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1531700
- 306 views
Original Research
Published on 07 Feb 2025
Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1528004
- 169 views
Editorial
Published on 07 Feb 2025
Editorial: Deciphering the regulatory role of transcription factors in cancer immune infiltration
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1563949
- 225 views
Review
Published on 07 Feb 2025
Advances in preclinical and clinical studies of oncolytic virus combination therapy
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1545542
- 353 views
Systematic Review
Accepted on 06 Feb 2025
Bibliometric analysis: A study of the microenvironment in cervical cancer (2000-2024)
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1508173
Editorial
Accepted on 06 Feb 2025
Editorial: Circadian Rhythms and Cancer Hallmarks: Toward Advances in Immune-Based Therapeutics, and Outcomes
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1571086